Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multifunctional theranostic nanoplatform based on HER2-specific liposomes loaded with IR783 for simultaneous PTT/PDT therapy and optical bioimaging.

Nanomedicine : nanotechnology, biology, and medicine·2026
Same author

Efficacy of Single and Fractionated Neutron Irradiation of Normal and Tumor Cells In Vitro.

Bulletin of experimental biology and medicine·2026
Same author

[Laparoscopic IPOM+ versus IPOM for ventral hernia repair - are there clear advantages? A retrospective analysis].

Khirurgiia·2026
Same author

[Overall survival prediction scale for patients with grade 4 brain astrocytoma].

Zhurnal voprosy neirokhirurgii imeni N. N. Burdenko·2026
Same author

Expert Consensus of the Russian Society of Cardiology, the Society of Heart Failure Specialists, the Russian Association of Oncologists, and the Eurasian Association of Cardio-Oncologists. "Cardioprotection 2025: Modern Approaches to Preventing Cardiovasculatoxicity in Antitumor Therapy". Part II. Primary Prevention of Cardiovasculatoxicity: a Strategy for Protecting the Myocardium and Vessels.

Kardiologiia·2025
Same author

The Use of High-Concentration Collagen-Based Composition and Gelatin Granules as Bioinks for Extrusion 3D Bioprinting of Porous-Structured Hydrogel Constructs.

Sovremennye tekhnologii v meditsine·2025

Related Experiment Video

Updated: Oct 17, 2025

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.3K

Specific Cytotoxicity of Targeted 177Lu and 212Pb-Based Radiopharmaceuticals.

A A Pankratov1, E R Nemtsova2, A D Plyutinskaya1

  • 1P. A. Hertsen Moscow Oncology Research Institute - Affiliated Branch of National Medical Research Radiological Centre, Ministry of Health of the Russian Federation, Moscow, Russia.

Bulletin of Experimental Biology and Medicine
|October 9, 2021
PubMed
Summary

New targeted radiopharmaceuticals using ZHER2 polypeptide demonstrated significant in vitro cytotoxic activity against HER2/neu-positive breast cancer cells (SK-BR3). This targeted approach shows promise for future preclinical studies in relevant tumor models.

Keywords:
177Lu and 212Pb radionuclidestargeted radiopharmaceutical

More Related Videos

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

7.8K
Preparation and Evaluation of 99mTc-labeled Tridentate Chelates for Pre-targeting Using Bioorthogonal Chemistry
10:54

Preparation and Evaluation of 99mTc-labeled Tridentate Chelates for Pre-targeting Using Bioorthogonal Chemistry

Published on: February 4, 2017

8.3K

Related Experiment Videos

Last Updated: Oct 17, 2025

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.3K
Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

7.8K
Preparation and Evaluation of 99mTc-labeled Tridentate Chelates for Pre-targeting Using Bioorthogonal Chemistry
10:54

Preparation and Evaluation of 99mTc-labeled Tridentate Chelates for Pre-targeting Using Bioorthogonal Chemistry

Published on: February 4, 2017

8.3K

Area of Science:

  • Nuclear medicine
  • Oncology
  • Radiopharmaceutical development

Background:

  • Targeted radiopharmaceuticals offer a promising approach for cancer therapy by delivering cytotoxic radiation directly to tumor cells.
  • The HER2/neu receptor is a validated target in breast cancer, making it an attractive target for molecularly targeted therapies.

Purpose of the Study:

  • To develop and evaluate the in vitro cytotoxic activity of two novel radiopharmaceutical preparations targeting the HER2/neu marker.
  • To compare the efficacy of these targeted radiopharmaceuticals against breast cancer cell lines with differential HER2/neu expression.

Main Methods:

  • Development of radiopharmaceutical preparations incorporating an artificial polypeptide (ZHER2) specific to the HER2/neu marker, labeled with either 177Lu or 212Pb.
  • In vitro evaluation of cytotoxic activity using two human breast cancer cell lines: SK-BR3 (high HER2/neu expression) and MCF-7 (low HER2/neu expression).
  • Assessment of cytotoxicity based on incubation period (24h vs. 72h) and comparison with non-targeted radionuclide salts.

Main Results:

  • Both radiopharmaceutical preparations exhibited significantly higher cytotoxic effects against SK-BR3 cells (high HER2/neu expression) compared to MCF-7 cells (low HER2/neu expression).
  • Cytotoxicity increased with longer incubation periods (72h vs. 24h).
  • The targeted radiopharmaceuticals demonstrated significantly greater cytotoxicity than radionuclide salts alone, highlighting the importance of the specific ligand.

Conclusions:

  • Targeted radiopharmaceuticals based on ZHER2 polypeptide show potent in vitro cytotoxic activity against HER2/neu-expressing breast cancer cells.
  • The findings support the potential of these novel radiopharmaceuticals for targeted cancer therapy.
  • Further in vivo preclinical studies in HER2/neu-expressing xenograft tumor models are warranted and appear promising.